A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia

Milena Kohn; Marc Delord; Maureen Chbat; Amina Guemriche; Fatiha Merabet; Anne-Laure Roupie; Naelle Lombion; Hassan Farhat; Thomas Longval; Aurelie Cabannes-Hamy; Juliette Lambert; Stephanie Marque-Juillet; Victoria Raggueneau; Jennifer Osman; Marc Spentchian; Sophie Rigaudeau; Philippe Rousselot; Caroline Besson

doi:10.3324/haematol.2021.280026

A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia

Milena Kohn, Marc Delord, Maureen Chbat, Amina Guemriche, Fatiha Merabet, Anne-Laure Roupie, Naelle Lombion, Hassan Farhat, Thomas Longval, Aurelie Cabannes-Hamy, Juliette Lambert, Stephanie Marque-Juillet, Victoria Raggueneau, Jennifer Osman, Marc Spentchian, Sophie Rigaudeau, Philippe Rousselot, Caroline Besson

Population Health Sciences

Research output: Contribution to journal › Letter › peer-review

13 Citations (Scopus)

Original language	English
Pages (from-to)	1454-1459
Number of pages	6
Journal	Haematologica
Volume	107
Issue number	6
DOIs	https://doi.org/10.3324/haematol.2021.280026
Publication status	Published - Jun 2022

Access to Document

10.3324/haematol.2021.280026

Cite this

Kohn, M., Delord, M., Chbat, M., Guemriche, A., Merabet, F., Roupie, A.-L., Lombion, N., Farhat, H., Longval, T., Cabannes-Hamy, A., Lambert, J., Marque-Juillet, S., Raggueneau, V., Osman, J., Spentchian, M., Rigaudeau, S., Rousselot, P., & Besson, C. (2022). A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia. Haematologica, 107(6), 1454-1459. https://doi.org/10.3324/haematol.2021.280026

@article{30da0170a7e54f68bc8f1f46fb70df40,

title = "A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia",

author = "Milena Kohn and Marc Delord and Maureen Chbat and Amina Guemriche and Fatiha Merabet and Anne-Laure Roupie and Naelle Lombion and Hassan Farhat and Thomas Longval and Aurelie Cabannes-Hamy and Juliette Lambert and Stephanie Marque-Juillet and Victoria Raggueneau and Jennifer Osman and Marc Spentchian and Sophie Rigaudeau and Philippe Rousselot and Caroline Besson",

year = "2022",

month = jun,

doi = "10.3324/haematol.2021.280026",

language = "English",

volume = "107",

pages = "1454--1459",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "6",

}

Kohn, M, Delord, M, Chbat, M, Guemriche, A, Merabet, F, Roupie, A-L, Lombion, N, Farhat, H, Longval, T, Cabannes-Hamy, A, Lambert, J, Marque-Juillet, S, Raggueneau, V, Osman, J, Spentchian, M, Rigaudeau, S, Rousselot, P & Besson, C 2022, 'A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia', Haematologica, vol. 107, no. 6, pp. 1454-1459. https://doi.org/10.3324/haematol.2021.280026

TY - JOUR

T1 - A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia

AU - Kohn, Milena

AU - Delord, Marc

AU - Chbat, Maureen

AU - Guemriche, Amina

AU - Merabet, Fatiha

AU - Roupie, Anne-Laure

AU - Lombion, Naelle

AU - Farhat, Hassan

AU - Longval, Thomas

AU - Cabannes-Hamy, Aurelie

AU - Lambert, Juliette

AU - Marque-Juillet, Stephanie

AU - Raggueneau, Victoria

AU - Osman, Jennifer

AU - Spentchian, Marc

AU - Rigaudeau, Sophie

AU - Rousselot, Philippe

AU - Besson, Caroline

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85126214667&partnerID=8YFLogxK

U2 - 10.3324/haematol.2021.280026

DO - 10.3324/haematol.2021.280026

M3 - Letter

SN - 0390-6078

VL - 107

SP - 1454

EP - 1459

JO - Haematologica

JF - Haematologica

IS - 6

ER -

A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia

Access to Document

Other files and links

Cite this